Plasma Fractionation Market to Grow at a CAGR of 7.5% During 2024-2032; Increased Demand for Plasma-derived Medicinal Products for Treating Immunological Disorders to Propel Market Expansion

The global plasma fractionation market size stood at USD 32.83 billion in 2023 and market is predicted to rise from USD 35.21 billion in 2024 to USD 62.83 billion by 2032, recording a CAGR of 7.5% from 2024 to 2032.

Fortune Business Insights™ presents this information in its report titled, “Plasma Fractionation Market Size, Share & Industry Analysis, By Product (Albumin, Immunoglobulin (Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)), Coagulation Factors (Factor IX, Factor VIII, Prothrombin Complex Concentrates, Fibrinogen Concentrates, and Others), Protease Inhibitors, and Others), By Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology, and Others), By End-user (Hospitals & Clinics, Clinical Research Laboratories, and Others), and Regional Forecast, 2024-2032”.  

Plasma fractionation is a production procedure to separate plasma proteins to create various plasma protein therapies. Key players are heavily investing in R&D initiatives and increasing manufacturing capabilities to introduce novel plasma-derived products. Increased demand for plasma-derived medicinal products for treating immunological, hemostatic, metabolic disorders, and other life-threatening disorders is driving market expansion.

The COVID-19 pandemic adversely impacted the market as plasma collection process interruptions amid the pandemic hindered the demand for plasma fractionation products.

Increasing Investments by Key Players in Building New Production Sites to Boost Market Expansion

In March 2023, Takeda Pharmaceutical Company Limited invested USD 764.6 million to develop a new plasma-derived therapy manufacturing unit in Osaka, Japan. The facility will be operative by 2030 and will boost the company’s manufacturing capacity in Japan fivefold.

Increasing Prevalence of Rare Genetic Disorders to Foster Market Growth

Plasma-derived medicinal products are highly preferred to exchange deficient proteins in an individual. They assist in treating rare conditions affecting a relatively smaller proportion of the population. The growing prevalence of different immunodeficiency and rare genetic disorders is driving the demand for plasma-derived therapies. Rising cases of bleeding disorders are boosting the sales of plasma fractionation products. Additionally, primary immunodeficiency is a set of 300 diseases characterized by recurrent chronic infections, autoimmunity, allergy, or inflammation. The increasing prevalence of rare genetic disorders and various immunodeficiency disorders is propelling plasma fractionation market growth.

On the other hand, the presence of plasma fractionation alternatives is impeding market expansion.

Increase in the Introduction of a Wide Range of Implants at Premium Prices by Key Players to Propel Market Growth

Key players, including CSL and Grifols, S.A., accounted for the highest of the global plasma fractionation market share. Leading plasma fractionation companies are highly investing in research and development and focusing on establishing new plasma collection centers to increase their market shares. In December 2022, CSL built a plasma manufacturing unit in Victoria, Australia. This new facility can process up to 9.2 million plasma equivalent liters per year, accelerating the current capacity by ninefold.

Notable Industry Development:

• October 2020: Grifols, S.A. completed the acquisition of  Green Cross fractionation plant based in Canada and 11 plasma collection centers based in the U.S.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614

List of the Companies Profiled in the Report:

• CSL (U.S.)


• Grifols, S.A (Spain)


• Takeda Pharmaceutical Company Limited (Japan)


• Kedrion S.p.A (Italy)


• Octapharma (Switzerland)


• Bio Products Laboratory Ltd. (U.K.)


• Biotest AG (Germany)


• LFB (France)

Further Report Findings-

• The market in North America was valued at USD 18.34 billion in 2023. The existence of key companies developing and launching innovative plasma-derived therapies and products is driving market growth in the region.


• Europe gained the second position in terms of market share owing to the rising incidence of immunodeficiency and bleeding disorders in the region.


• Latin America and the Middle East & Africa are set to register comparatively slower growth over the forecast period due to the growing prevalence of autoimmune diseases in these regions.


• In terms of product, the immunoglobulin segment led the market in 2023. Increasing demand for IVIG products for various primary and secondary immunodeficiency disorders is driving segment growth.


• Based on the application, the immunology & neurology segment is set to rise at a higher growth rate during the forecast period. Rising cases of immunodeficiency and autoimmune diseases are fueling segment growth.

Table of Segmentation